Receptorium histamini H3
| Receptorium histamini H3 | |||||
|---|---|---|---|---|---|
| Alia | HRH3, GPCR97 | ||||
| Fontes ext. |
OMIM: 604525 | ||||
| Locus geni (homo) | |||||
 | |||||
| Chr. | Chromosoma 20 (humanum) | ||||
Receptorium histamini H3 (abbreviatura:; H3R) est receptorium histamini praesynapticum et familiae receptoriorum proteino G copulatorum. Receptoria imprimis in systemate nervosi centrali inveniuntur atque in systemate peripherico velut in intestinis.
An anno 1990 duos subtypos receptorii investigatum esse putatum est[1].
Antagonista receptorii histamini H3 tempore futuro therapiis contra epilepsias vel morbos neurodegenerativos levare possint[2].
Historia[recensere | fontem recensere]
Anno 1983 receptorium H3 primum inventum est[3], quod periodico scientifico Nature dignum articuli proprii visum est. Anno 1988 in corticibus cerebralium rattorum liberationem serotonini per histaminum receptoriorum H3 ope inhiberi demonstratum est[4]. Effectus in infarctu cordis receptorii H3 anno 1997 divulgatus atque fructus therapiae ischaemiae cardialis propositus est. Iam prius in ischaemia cardiali protracta decessio ATP cum liberatione maxima NE ex cellulis demersis NET sympathici ope observabatur. Tunc experimenta receptorium H3 effectus hos detrimentosos in parte revertere posse demonstraverunt[5].
Genetica[recensere | fontem recensere]
Genum nomine HRH3 in hominibus in chromosomate 20 (20q13.33) locatum est.
Distributio[recensere | fontem recensere]
H3R imprimis in systemate nervosi centrali inveniuntur atque in systemate peripherico velut in intestinis[6]. In cerebro receptorium in neuronibus praesynapticis corticis, potissimum nucleorum basalium[7], velut hippocampi, nuclei accumbentis, substantiae nigrae, locatum est.
Notae[recensere | fontem recensere]
- ↑ West R. E. Jr., Zweig A., Shih N. Y., Siegel M. I., Egan R. W., Clark M. A. (1990). "Identification of two H3-histamine receptor subtypes". Molecular pharmacology 38 (5): 610-3
- ↑ Bhowmik M., Khanam R., Vohora D. (2012). "Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives". British journal of pharmacology 167 (7): 1398-414
- ↑ Arrang J. M., Garbarg M., Schwartz J. C. (1983). "Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor". Nature 302 (5911): 832-7
- ↑ Schlicker E., Betz R., Göthert M. (1988). "Histamine H3 receptor-mediated inhibition of serotonin release in the rat brain cortex". Naunyn-Schmiedeberg's archives of pharmacology 337 (5): 588-90
- ↑ Hatta E., Yasuda K., Levi R. (1997). "Activation of histamine H3 receptors inhibits carrier-mediated norepinephrine release in a human model of protracted myocardial ischemia". The journal of pharmacology and experimental therapeutics 283 (2): 494-500
- ↑ Bertaccini G., Coruzzi G. (1995). "An update on histamine H3 receptors and gastrointestinal functions". Digestive diseases and sciences 40 (9): 2052-63
- ↑ Brown R. E., Stevens D. R., Haas H. L. (2001). "The physiology of brain histamine". Progress in neurobiology 63 (6): 637-72
Nexus interni
 |
